Last edition
News about Global Pharma
Aspire Pharma acquires Charlwood Pharma
Aspire Pharma, a UK-based specialty generics pharma business, has announced the acquisition of Charlwood Pharma Ltd — a privately-owned company specialising in the research and development of niche generic medicines. The deal marks the culmination of a successful multi-year collaboration between the two organisations.
Global Pharma | 21/10/2025 | By Dineshwori | 161
Waters Corporation Unveils Xevo Charge Detection MS for Advanced Biomolecule Analysis
The new Xevo CDMS system by Waters Corporation enables measurement of large biomolecules to support Research and Development (R&D) in gene and protein-based therapies.
Global Pharma | 21/10/2025 | By Dineshwori | 118
ManaMed Secures FDA Clearance for Next-Generation Tubeless Compression System, PlasmaFlow X
ManaMed, a US-based global leader in orthopedic mobility and post-operative rehabilitation equipment, has received FDA 510(k) clearance for PlasmaFlow X, its next-generation tubeless sequential compression system designed to redefine recovery and enhance patient comfort.
Global Pharma | 21/10/2025 | By Dineshwori | 147
Korean biotech company SK Biopharmaceuticals and Brazil-based Eurofarma have established a joint venture, Mentis Care, in Canada to commercialise an AI-powered epilepsy management platform. The new company marks SK Biopharmaceuticals’ full-scale expansion into digital healthcare beyond its innovative drug development portfolio.
Global Pharma | 21/10/2025 | By Dineshwori | 201
Fabhalta from Novartis Meets Phase-III Goal in Slowing Kidney Decline in IgAN Patients
Fabhalta (iptacopan) from Novartis met its Phase III primary endpoint, slowing kidney function decline in IgA nephropathy (IgAN) patients. The first approved complement inhibitor for IgAN, Fabhalta builds on its 2024 U.S. accelerated approval, with data supporting a 2026 traditional FDA submission.
Global Pharma | 17/10/2025 | By Dineshwori | 117
NAYA Therapeutics, a US-based clinical-stage biopharmaceutical company developing next-generation cancer therapies, has entered into a research and manufacturing partnership with China’s Alpha Nuclide, a radiopharmaceutical solutions company leading global efforts in Astatine-211 (211At) supply and CDMO services.
Global Pharma | 17/10/2025 | By Dineshwori | 155
Graph Secures USD 3 Million Seed Funding from Bessemer for AI-Driven Drug Safety
California-based Graph AI has announced its USD 3 Million Seed round, led by Bessemer Venture Partners. The investment will enable Graph to accelerate product innovation, expand its engineering team, and drive global market adoption.
Global Pharma | 17/10/2025 | By Dineshwori | 131
Sanofi Names Montpellier Global Hub for Autoimmune Disease Research
Sanofi, in partnership with the Immun4Cure University Hospital Institute in Montpellier, has launched a Translational Centre of Excellence focused on developing treatments for autoimmune and inflammatory diseases. The centre aims to place patients at the core of R&D, spanning early research through advanced clinical trials.
Global Pharma | 16/10/2025 | By Dineshwori | 171
AstraZeneca opens expanded manufacturing facility in Texas
AstraZeneca’s USD 445 million investment will support global manufacturing of Lokelma
Global Pharma | 16/10/2025 | By Dineshwori | 129
PENTAX Medical Sells C2 CryoBalloon Technology to Merit Medical Systems
PENTAX Medical, a division of the Japanese med-tech company HOYA Group and a global leader in flexible reusable endoscopy, has signed an asset purchase agreement with the American healthcare technology company Merit Medical Systems for the sale of its C2 CryoBalloon technology.
Global Pharma | 16/10/2025 | By Dineshwori | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy